At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CMPS COMPASS Pathways plc
Closed 08-27 16:00:00 EDT
14.64
+0.03
+0.21%
盘后14.72
+0.08+0.57%
19:56 EDT
High14.93Low14.40Vol1.66M
Open14.63D1 Closing14.61Amplitude3.63%
Mkt Cap2.02BTradable Cap1.57BTotal Shares138.00M
T/O24.33MT/O Rate1.55%Tradable Shares107.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Unusually active option classes on open August 26th
TIPRANKS  ·  08-26 21:40
Unusually active option classes on open August 26th
COMPASS Pathways (CMPS) Nears FDA Filing for COMP360 Following a Valuation Question
Simply Wall St.  ·  08-26 19:26
COMPASS Pathways (CMPS) Nears FDA Filing for COMP360 Following a Valuation Question
Compass Pathways (CMPS) Earnings Call Highlights COMP360’s Path
TIPRANKS  ·  08-21
Compass Pathways (CMPS) Earnings Call Highlights COMP360’s Path
How COMPASS Pathways’ VA Psilocybin Trial (CMPS) Has Reframed Its Veteran Mental Health Ambitions
Simply Wall St.  ·  08-20
How COMPASS Pathways’ VA Psilocybin Trial (CMPS) Has Reframed Its Veteran Mental Health Ambitions
Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS Pathways (CMPS)
TIPRANKS  ·  08-13
Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS Pathways (CMPS)
COMPASS Pathways (CMPS) Gets a Buy from Evercore ISI
TIPRANKS  ·  08-10
COMPASS Pathways (CMPS) Gets a Buy from Evercore ISI
Analysts’ Top Healthcare Picks: COMPASS Pathways (CMPS), Trulieve Cannabis (TRLV)
TIPRANKS  ·  08-08
Analysts’ Top Healthcare Picks: COMPASS Pathways (CMPS), Trulieve Cannabis (TRLV)
Compass Pathways is Maintained at Overweight by Morgan Stanley
Dow Jones  ·  08-07
Compass Pathways is Maintained at Overweight by Morgan Stanley
Compass Pathways price target raised to $22 from $17 at B. Riley
TIPRANKS  ·  08-06
Compass Pathways price target raised to $22 from $17 at B. Riley
RBC Adjusts PT on COMPASS Pathways to $21 From $22, Maintains Outperform Speculative Risk Rating
MT Newswires Live  ·  08-06
RBC Adjusts PT on COMPASS Pathways to $21 From $22, Maintains Outperform Speculative Risk Rating
Ireland's GH Research Q2 Net Loss Widens on Higher R&D Costs
Reuters  ·  08-06
Ireland's GH Research Q2 Net Loss Widens on Higher R&D Costs
Scholar Rock Q2 Net Loss Narrows
Reuters  ·  08-06
Scholar Rock Q2 Net Loss Narrows
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin
THOMSON REUTERS  ·  08-06
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin
Compass Pathways Grants New-Hire Inducement Equity Awards at USD 11.25 Per Share
Reuters  ·  08-06
Compass Pathways Grants New-Hire Inducement Equity Awards at USD 11.25 Per Share
Compass Pathways Announces New Employee Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  08-06
Compass Pathways Announces New Employee Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Compass Pathways Plc Files for Mixed Shelf Offering; Size not Disclosed - SEC Filing
THOMSON REUTERS  ·  08-06
Compass Pathways Plc Files for Mixed Shelf Offering; Size not Disclosed - SEC Filing
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS), Geron (GERN) and Azenta (AZTA)
TIPRANKS  ·  08-06
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS), Geron (GERN) and Azenta (AZTA)
Compass Pathways PLC Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-05
Compass Pathways PLC Reports Results for the Quarter Ended June 30 - Earnings Summary
Compass Pathways Publishes Investor Presentation on Comp360 Psilocybin Program, FDA Filing Progress and Launch Plans
Reuters  ·  08-05
Compass Pathways Publishes Investor Presentation on Comp360 Psilocybin Program, FDA Filing Progress and Launch Plans
Earnings Flash (CMPS) Compass Pathways Posts Q2 Loss $1.88 a Share, vs. FactSet Est of $0.33 Loss
MT Newswires Live  ·  08-05
Earnings Flash (CMPS) Compass Pathways Posts Q2 Loss $1.88 a Share, vs. FactSet Est of $0.33 Loss

Introduction

Company Name.
COMPASS Pathways plc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Issue price:
--